BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

821 related articles for article (PubMed ID: 15538739)

  • 1. Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer.
    Jakob C; Aust DE; Meyer W; Baretton GB; Schwabe W; Häusler P; Becker H; Liersch T
    J Pathol; 2004 Dec; 204(5):562-8. PubMed ID: 15538739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy.
    Jakob C; Liersch T; Meyer W; Baretton GB; Schwabe W; Häusler P; Kulle B; Becker H; Aust DE
    Am J Surg Pathol; 2006 Sep; 30(9):1169-74. PubMed ID: 16931962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
    Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
    J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TS and DPD mRNA levels on formalin-fixed paraffin-embedded specimens as predictors for distant recurrence of rectal cancer treated with preoperative chemoradiotherapy.
    Tanaka K; Saigusa S; Toiyama Y; Koike Y; Okugawa Y; Yokoe T; Inoue Y; Kobayashi M; Miki C; Kusunoki M
    J Surg Oncol; 2012 May; 105(6):529-34. PubMed ID: 22006578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation.
    Stoehlmacher J; Goekkurt E; Mogck U; Aust DE; Kramer M; Baretton GB; Liersch T; Ehninger G; Jakob C
    Cancer Lett; 2008 Dec; 272(2):221-5. PubMed ID: 18722050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Kornmann M; Schwabe W; Sander S; Kron M; Sträter J; Polat S; Kettner E; Weiser HF; Baumann W; Schramm H; Häusler P; Ott K; Behnke D; Staib L; Beger HG; Link KH
    Clin Cancer Res; 2003 Sep; 9(11):4116-24. PubMed ID: 14519634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.
    Salonga D; Danenberg KD; Johnson M; Metzger R; Groshen S; Tsao-Wei DD; Lenz HJ; Leichman CG; Leichman L; Diasio RB; Danenberg PV
    Clin Cancer Res; 2000 Apr; 6(4):1322-7. PubMed ID: 10778957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymidine phosphorylase mRNA level predicts survival of patients with advanced oropharyngeal cancer.
    Ijuin T; Nibu K; Doi K; Inoue H; Saitoh M; Ohtsuki N; Makino K; Amatsu M
    Acta Otolaryngol; 2007 Mar; 127(3):305-11. PubMed ID: 17364369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined evaluation of dihydropyrimidine dehydrogenase and thymidine phosphorylate mRNA levels in tumor predicts the histopathological effect of 5-fluorouracil-based chemoradiotherapy.
    Tateishi Y; Tatemoto Y; Ohno S; Morishita K; Ueta E; Yamamoto T
    Cancer Lett; 2009 Feb; 274(2):187-93. PubMed ID: 18986760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
    Yamada H; Iinuma H; Watanabe T
    Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test.
    Kakimoto M; Uetake H; Osanai T; Shirota Y; Takagi Y; Takeshita E; Toriya Y; Danenberg K; Danenberg PV; Sugihara K
    Cancer Lett; 2005 Jun; 223(1):103-11. PubMed ID: 15890242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical analysis of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer (cUICC II/III): correlation with histopathologic tumor regression after 5-fluorouracil-based long-term neoadjuvant chemoradiotherapy.
    Jakob C; Liersch T; Meyer W; Baretton GB; Häusler P; Schwabe W; Becker H; Aust DE
    Am J Surg Pathol; 2005 Oct; 29(10):1304-9. PubMed ID: 16160472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung.
    Ishihama H; Chida M; Araki O; Karube Y; Seki N; Tamura M; Umezu H; Honma K; Masawa N; Miyoshi S
    Jpn J Clin Oncol; 2009 Jan; 39(1):33-6. PubMed ID: 19015148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.
    Ichikawa W; Uetake H; Shirota Y; Yamada H; Nishi N; Nihei Z; Sugihara K; Hirayama R
    Clin Cancer Res; 2003 Feb; 9(2):786-91. PubMed ID: 12576451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression profile of 5-fluorouracil metabolic enzymes in primary colorectal cancer: potential as predictive parameters for response to fluorouracil-based chemotherapy.
    Kinoshita M; Kodera Y; Hibi K; Nakayama G; Inoue T; Ohashi N; Ito Y; Koike M; Fujiwara M; Nakao A
    Anticancer Res; 2007; 27(2):851-6. PubMed ID: 17465211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up.
    Lassmann S; Hennig M; Rosenberg R; Nährig J; Schreglmann J; Krause F; Poignee-Heger M; Nekarda H; Höfler H; Werner M
    Int J Colorectal Dis; 2006 Apr; 21(3):238-47. PubMed ID: 16132996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase mRNA expression correlate with prolonged survival in resected non-small-cell lung cancer.
    Grimminger PP; Schneider PM; Metzger R; Vallböhmer D; Hölscher AH; Danenberg PV; Brabender J
    Clin Lung Cancer; 2010 Sep; 11(5):328-34. PubMed ID: 20837458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymidylate synthase gene polymorphism affects the response to preoperative 5-fluorouracil chemoradiation therapy in patients with rectal cancer.
    Hur H; Kang J; Kim NK; Min BS; Lee KY; Shin SJ; Keum KC; Choi J; Kim H; Choi SH; Lee MY
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):669-76. PubMed ID: 20932673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
    Schneider S; Uchida K; Brabender J; Baldus SE; Yochim J; Danenberg KD; Salonga D; Chen P; Tsao-Wei D; Groshen S; Hoelscher AH; Schneider PM; Danenberg PV
    J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.